Vancomycin

Where the papers sit

17 papers from the last 6 months study vancomycin directly · updated from PubMed 9 Oct 2026

• Targeted Antibacterial Delivery

  Localized vancomycin delivery is moving toward multifunctional hydrogels, nanoparticles and conjugates that combine bacterial trapping, biofilm disruption and anti-inflammatory activity. Applications span endophthalmitis, keratitis, musculoskeletal infection, oral Clostridioides difficile infection and pneumococcal colonization. Bone graft elution and intranasal administration seek high local concentrations while limiting systemic exposure. Sensor-integrated platforms add concentration control, but durability, safety and clinical translation remain open.

  12 papers · 70.6%

• Antibiotic Toxicity and Kidney Injury

  Vancomycin safety work centers on acute kidney injury, with concomitant piperacillin/tazobactam repeatedly compared with cefepime or meropenem. The combination is associated with greater renal risk, supporting more cautious empiric selection and renal monitoring. Vancomycin-induced DRESS adds severe immune toxicity and highlights difficult decisions about treatment and eosinophilia resolution. The field is balancing broad initial coverage against preventable toxicity and delayed recognition of adverse reactions.

  3 papers · 17.6%

• Pharmacokinetic Monitoring and Modeling

  Population pharmacokinetic modeling is moving toward machine-learning selection, while point-of-care sensors aim to make vancomycin monitoring faster and less invasive. Support vector machines and multilayer perceptrons are evaluated against conventional model development. Molecularly imprinted polymer sensors and microneedle sampling extend measurement beyond routine blood draws. Clinical validation must still show that these tools improve dose selection and outcomes.

  2 papers · 11.8%